Pneumonia is a common lung infection caused by a variety of microorganisms such as bacteria, virus, fungi and parasites. In pneumonia the air sacs of lungs that are known as alveoli are filled with fluid or pus causing inflammation. The common symptoms of pneumonia are cough with phlegm, sneezing, sore throat, chills, fever and trouble in breathing. Pneumonia is usually a mild disease but under certain situations can be lethal. Children, elderly people and those with recent viral infections, lung disease and heart disease are at higher risk of developing pneumonia compared to general population. Pneumonia is of different types depending on the way it has been acquired by people such community acquired pneumonia (CAP), hospital acquired pneumonia (HAP) and healthcare associated pneumonia as patient may also develop pneumonia during their visits to other healthcare setting such as nursing homes, dialysis centers and outpatient clinics. Others are aspiration pneumonia and atypical pneumonia. Pneumonia is one of the most common hospital acquired infection.
Request Brochure –
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1735
The global market for pneumonia is segmented broadly into treatment drugs and prevention vaccines market. Usually antibiotics used to treat pneumonia include cephalosporins, penicillin, tetracyclines, fluoroquinolones, amoxicillin, clavulanic acid and vancomycin. Earlier, penicillin was widely used to treat pneumonia caused by bacteria pnemococcal pneumonia but due to wide spread use of broad spectrum antibiotics has resulted into significant drug resistance. Penicillin is still used but only after confirming the sensitivity of the bacteria towards this antibiotic. Pneumococcal conjugate vaccine such as PCV13 and pneumococcal polysaccharide vaccines such as PPV23 and Pneumovax are used to prevent pneumococcal diseases. The major players operating in this market are Sanofi, Eli Lilly, AstraZeneca, Merck & Co. Novartis, GlaxoSmithCline, Pfizer and Baxter International Inc.
Pre Pneumonia Drugs & Vaccines Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=1735<ype=S
The market for pneumonia drugs and vaccines is expected to grow under the impact of drivers such as increasing aging population as aging population are more susceptible to developing pneumonia and increasing prevalence of pneumonia among children. According to WHO, every year approximately 1.2 million children under the age of five years die because of pneumonia. WHO also reports only 30% of children suffering from pneumonia get required antibiotics for the treatment of pneumonia. This disease is most prevalent in South Asia and African countries.
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insights to thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyse information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
Contact
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com/
The Global COVID-19 Impact on Vaccines and Drugs Market study involved the extensive use of both primary and secondary sources.
The research process involved the study of various factors affecting the industry to identify the key players, competitive landscape, key market dynamics, and key player strategies.The Global COVID-19 Vaccines Market is projected to reach USD 1,401 million by 2025 from USD 2,273 million in 2022, at a CAGR of -14.9% during the forecast period.
The growth of the COVID vaccines market is attributed majorly to the rising number of people infected with COVID-19 and increasing funding for vaccine development.The Global COVID-19 Drugs Market is projected to reach USD 2 million by 2025 from USD 165 million in 2020, at a CAGR of -57.8% during the forecast period.The growth of the COVID drugs market is primarily attributed to use of repurposed drugs for compassionate use, and the emergence of alternative therapies such as convalescent plasma therapy which were earlier used for treating epidemic diseases such as SARS, MERS, and H1N1.
Moreover, collaborations between global organizations and governments of various nations to promote the supply of essential drugs and medical supplies are fueling the market growth.Currently, the R landscape for COVID-19 vaccines includes 115 vaccine candidates.
The most advanced candidates that have recently moved into clinical development are:– mRNA-1273 from Moderna– Ad5-nCoV from CanSino Biologics– INO-4800 from Inovio– LV-SMENP-DC and pathogen-specific aAPC from Shenzhen Geno-Immune Medical InstituteRequest Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=112248051Drugs targeting COVID-19 are falling majorly in the category of repurposed drugs that have already entered phase 2 of clinical development.As the COVID-19 pandemic progresses, pharmaceutical and biotechnology companies are increasing their efforts to find a cure for the disease.
In just a few weeks, scientists have found a list of molecules that target COVID-19.
